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Background
Coenzyme Q-10 (ubiquinone) is a small hydrophobic
substance that acts as an electron carrier in the mito-
chondrial respiratory chain. Its main activity is to pro-
tect DNA, proteins and lipids from oxidative stress. In
the literature, a role of brain oxidative metabolism in
the pathogenesis of migraine has been hypothesized [1].
Few clinical trials are described using coenzyme Q-10 in
migraine prophylaxis, even in pediatrics [2-4]. The aim
of this work was to present our experience of migraine
prevention, prescribing coenzyme Q-10 to 20 adult
patients with migraine without aura.
Materials and methods
Patients were enrolled in a tertiary headache center and
followed for a period of 60 days (visit 1 and visit 2). The
dose of coenzyme Q-10 was 200 mg/day. Visual analo-
gue scale (VAS) was used to measure pain.
Results
In our cohort, male/female ratio was 1:5, while the
mean age was 32.1 years (range, 22-49 years). Patients
had a relatively short history of disease (mean 5.6 years;
range 2-18), indeed only 2 of them were on a first-line
treatment whereas coenzyme Q-10 was the starting
therapy for others. We noticed a significant reduction of
the number of crises at visit 2 (mean 3.15 vs 0.9, p <
0.05), as well as VAS score (mean 6.65 vs 1.45, p < 0.05)
and monthly days of headache (mean 6.3 vs 1.5, p <
0.05). No one showed side effects, body weight did not
vary (mean 56.55 vs mean 56.65) and patients did not
even experience drastic weight loss or gain. The drug
was well tolerated with a mean satisfaction score of 7.65
(range, 0-10). Moreover, patients reported positive
effects on fatigue.
Conclusions
Coenzyme Q-10 is a safe and effective therapy for
migraine prophylaxis.
Written informed consent to publish was obtained
from the patient(s).
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